CN Patent
CN105120864A — 表现出抗癌活性和抗增殖活性的2-氨基嘧啶-6-酮及类似物
Assigned to Deciphera Pharmaceuticals LLC · Expires 2015-12-02 · 10y expired
What this patent protects
本发明描述式I的化合物, 其可通过抑制c-FMS(CSF-IR)、c-KIT和/或PDGFR激酶用于治疗癌症、自身免疫疾病和骨代谢病症。这些化合物还可用于治疗由c-FMS、c-KIT或PDGFR激酶介导的其它哺乳动物疾病。
USPTO Abstract
本发明描述式I的化合物, 其可通过抑制c-FMS(CSF-IR)、c-KIT和/或PDGFR激酶用于治疗癌症、自身免疫疾病和骨代谢病症。这些化合物还可用于治疗由c-FMS、c-KIT或PDGFR激酶介导的其它哺乳动物疾病。
Drugs covered by this patent
- Romvimza (VIMSELTINIB) · Deciphera Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.